The following government grants in the FederalGrants.com database contain the term National Institutes of Health in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
| Grant Title | CFDA | Funding Number |
| Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional) |
93.273 |
PAR-25-158 |
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional) |
93.242 |
PAR-25-290 |
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional) |
93.242 |
PAR-25-291 |
| Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed) |
93.233, 93.837, 93.838, 93.839 |
RFA-HL-26-019 |
| Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed) |
93.233, 93.837, 93.838, 93.839 |
RFA-HL-26-018 |
| Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) |
93.242, 93.313 |
PAR-25-282 |
| Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) |
93.242 |
PAR-25-226 |
| Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed) |
93.233, 93.837, 93.838, 93.839 |
RFA-HL-26-020 |
| Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) |
93.242, 93.313 |
PAR-25-281 |
| Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) |
93.233, 93.837, 93.838, 93.839 |
RFA-HL-26-016 |
| BRAIN Initiative: Promoting Equity Through BRAIN Technology Partnerships (R34 - Clinical Trials Not Allowed) |
93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867 |
RFA-NS-25-016 |
| Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) |
93.233, 93.837, 93.838, 93.839 |
RFA-HL-26-017 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) |
93.393, 93.394, 93.395, 93.396, 93.399 |
PAR-25-171 |
| Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed) |
93.855 |
RFA-AI-24-076 |
| Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional) |
93.242, 93.279 |
PAR-25-278 |
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) |
93.399 |
PA-25-294 |
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) |
93.399 |
PA-25-295 |
| Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required) |
93.310 |
RFA-RM-24-008 |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) |
93.393 |
PAR-25-248 |
| Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) |
93.399 |
PAR-25-254 |
| Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) |
93.213 |
PAR-25-274 |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) |
93.242 |
PAR-25-286 |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed) |
93.242 |
PAR-25-287 |
| Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R41 - Clinical Trials Optional) |
93.279 |
RFA-DA-26-017 |
| NINR Resources and Related Research Projects in Firearm Injury Prevention (R24 Clinical Trial Not Allowed) |
93.313, 93.361 |
RFA-NR-25-002 |
| Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Clinical Trials Optional) |
93.279 |
RFA-DA-26-016 |
| NEI Postbaccalaureate Opportunities in Vision Science (POVS) Research Education Program (R25 Clinical Trial Not Allowed) |
93.867 |
PAR-24-290 |
| Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) |
93.213 |
PAR-25-268 |
| Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed) |
93.279, 93.853 |
RFA-NS-25-027 |
| NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) |
93.213 |
PAR-25-267 |
| Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed) |
93.242, 93.279, 93.853 |
RFA-MH-26-111 |
| Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required) |
93.121, 93.273, 93.279, 93.307, 93.313, 93.399 |
PAR-26-001 |
| Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed) |
93.242, 93.279, 93.853 |
RFA-MH-26-110 |
| NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) |
93.279 |
PAR-25-261 |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) |
93.172, 93.173, 93.233, 93.242, 93.273, 93.279, 93.361, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.865, 93.866, 93.867 |
PAR-25-148 |
| Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) |
93.242 |
PAR-25-034 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) |
93.242 |
PAR-25-035 |
| Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) |
93.394, 93.395 |
PAR-25-106 |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) |
93.121, 93.395, 93.396 |
PAR-25-107 |
| Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) |
93.172, 93.213, 93.242, 93.286, 93.313, 93.846, 93.853, 93.866, 93.867 |
PAS-25-190 |
Search Results 401-440 of 15475
[Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 [Next] |
